Skip to main content
CGEM
NASDAQ Life Sciences

Zipalertinib NDA Filed Under FDA Real-Time Review for First-Line EGFR ex20ins NSCLC

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$10.35
Mkt Cap
$661.544M
52W Low
$7.72
52W High
$23.19
52W Position info
34% above low
Off High info
55% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

CGEM sits 34% above its 52-week low of $7.72.

Summary

Partner Taiho Oncology completed the NDA submission for zipalertinib plus platinum chemotherapy in first-line EGFR exon 20 insertion NSCLC, filed under the FDA's Real-Time Oncology Review program. This closes out the submission Cullinan flagged in its October 1 8-K, when it initiated the filing under RTOR. The application rests on the Phase 3 REZILIENT3 interim analysis, which showed a statistically significant PFS improvement over chemotherapy alone (14.5 vs 8.5 months), data already presented at WCLC in September. Cullinan gets $30M on a second-line U.S. approval and $100M on a first-line approval, meaningful against a roughly $660M market cap. The next hard checkpoint is FDA acceptance of the filing and assignment of a PDUFA target action date; no date has been set yet.

At the time of this announcement, CGEM was trading at $10.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $661.5M. The 52-week trading range was $7.72 to $23.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CGEM - Latest Insights

CGEM
Nov 08, 2026, 10:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.51
Real-time Price: $10.39 info
Change: -$1.12 (-10%) info
Market Cap: $661.544M info
CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $10.39 info
Change: -$2.96 (-22%) info
Market Cap: $661.544M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $10.39 info
Change: -$4.16 (-29%) info
Market Cap: $661.544M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $10.39 info
Change: -$6.49 (-38%) info
Market Cap: $661.544M info
CGEM
Sep 14, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.60
Real-time Price: $10.39 info
Change: -$10.21 (-50%) info
Market Cap: $661.544M info